Understanding nontuberculous mycobacterial lung disease: it’s been a long time coming [version 1; referees: 4 approved]
With a surprising predictability, most studies and reviews addressing therapy for nontuberculous mycobacterial (NTM) lung disease either start or end by mentioning the paucity of data from randomized and controlled trials. That is a legitimate criticism for NTM lung disease therapy, but it also some...
Main Authors: | David E. Griffith, Timothy R. Aksamit |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2016-11-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | https://f1000research.com/articles/5-2797/v1 |
Similar Items
-
Advances in understanding COPD [version 1; referees: 3 approved]
by: Gary P. Anderson
Published: (2016-09-01) -
Recent advances in understanding and treating ARDS [version 1; referees: 2 approved]
by: Rebecca M. Baron, et al.
Published: (2016-04-01) -
Recent advances in understanding acute respiratory distress syndrome [version 1; referees: 2 approved]
by: Peter Wohlrab, et al.
Published: (2018-03-01) -
What’s new in the management of adult bronchiectasis? [version 1; referees: 2 approved]
by: Usma Koser, et al.
Published: (2017-04-01) -
Advances in Laryngoscopy [version 1; referees: 2 approved]
by: Michael Aziz
Published: (2015-12-01)